182439-41-4

Usage

Uses

Used in Pharmaceutical Industry:
N-(piperidin-4-yl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamide is used as a reagent for the preparation of lomitapide mesylate crystal forms. Lomitapide mesylate is a microsomal triglyceride transfer protein inhibitor, which plays a crucial role in lowering the level of low-density lipoprotein cholesterol in plasma. N-(piperidin-4-yl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamide is particularly useful in the treatment of patients with homozygous familial hypercholesterolemia, a condition characterized by extremely high levels of LDL cholesterol.
Additionally, N-(piperidin-4-yl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamide is also utilized in the synthesis of lomitapide (L469435) metabolite, further expanding its applications in the pharmaceutical sector. The compound's unique structural features and reactivity contribute to the development of effective treatments for various health conditions related to cholesterol management.

Upstream product

• 182439-40-3 N-(1-benzylpiperidin-4-yl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamide 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 128796-39-4 4-trifluoromethylphenylboronic acid 
• 88-67-5 2-Iodobenzoic acid 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 84392-17-6 4'-(trifluoromethyl)-2-biphenylcarboxylic acid 

Downstream Products

• 202914-84-9 N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4’-(trifluoromethyl)[1,1‘-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-9H-fluorene-9-carboxamide methanesulfonate 
• 182431-12-5 9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide 
• 594844-53-8 [4-(4'-trifluoromethylbiphenyl-2-carbonylamino)piperidin-1-yl]acetic acid ethyl ester 

Relevant academic research and scientific papers

Synthetic method of lomitapide-D8

The invention provides a synthetic method of lomitapide-D8. The method comprises the following steps: 1) performing a halogenation reaction on a compound 2a and hydrobromic acid to obtain a compound 2; 2) carrying out a hydrogen abstraction reaction on a compound 1 and n-butyllithium, and then adding the compound 2 to carry out a substitution reaction to prepare a compound 3; 3) performing a condensation reaction on the compound 3 and a compound 4 to obtain a compound 5; 4) performing a condensation reaction on a compound 6 and a compound 7 to obtain a compound 8; 5) removing tert-butyloxycarbonyl protection from the compound 8 by utilizing trifluoroacetic acid to obtain a compound 9; and 6) subjecting the compound 5 and the compound 9 to a substitution reaction to obtain the lomitapide-D8. Through the method, deuterated tetrahydrofuran with relatively low price is used as a raw material to synthesize the deuterated 1,4-dibromobutane-D8 for the first time, the deuterated lomitapide-D8is successfully synthesized, and a conventional synthesis route is changed, so that deuterated atoms which are difficult to obtain reach the maximum atom economic effect.

AMORPHOUS FORM OF LOMITAPIDE MESYLATE

Provided is novel amorphous form of lomitapide mesylate salt and process for preparation thereof.

PROCESS FOR THE PREPARATION OF LOMITAPIDE

The present invention relates to a process for preparing Lomitapide or its pharmaceutically acceptable salt thereof having high purity with acceptable levels of impurities.

ESTER COMPOUND AND MEDICINAL USE THEREOF

A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1") (wherein ???R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; ???X is -COO- or -CON(R10)-; ???R3 and R4 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; ???R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; ???R8 and R9 are each independently hydrogen atom, C1-C6 alkyl, -CON(R18)(R19) or -COO(R20), etc.; ???ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; ???Alk1 and Alk2 are each independently alkanediyl, etc.; ???l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.

Biphenyl derivatives, production thereof and uses as medicines

The present invention relates to biphenyl derivatives of general formula wherein Rato Rgand n are defined as in claim 1, the isomers and salts thereof, particularly the physiologically acceptable salts thereof, which are valuable inhibitors of the microsomal triglyceride-transfer protein (MTP), medicaments containing these compounds and their use, as well as the preparation thereof.